<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377844</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-418</org_study_id>
    <nct_id>NCT01377844</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Efficacy and Safety of EGT0001442 Compared With Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Diet and Exercise and up to One Oral Anti-diabetes Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of EGT0001442 in lowering glycosylated
      Hemoglobin (HbA1c, A laboratory test to diagnose three months average of blood sugar)levels
      at 24th week from baseline, when compared to placebo group(no diabetic medication given). The
      secondary aim of the study is to evaluate the efficacy of EGT0001442 in lowering fasting
      blood glucose at the weeks 2 and 24 and comparing the results with placebo group. This study
      assess the efficacy of EGT0001442 based on the proportion of subjects who reach the American
      Diabetes Association (ADA) target of HbA1c of &lt; 7% in EGT0001442 group and comparison with
      placebo. The study also evaluates the effect of EGT0001442 on systolic, diastolic pressures,
      body weight and compare with the respective placebo groups.This study also assess the change
      from baseline in HbA1c overtime, from week 1 to week 96. Finally, to assess the safety of
      EGT0001442 in the Type 2 Diabetic patients (adult/maturity onset).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EGT0001442 is a compound that may inhibit the effect of other compounds in the body known as
      sugar transporters. The use of EGT0001442 may enhance the elimination of glucose from the
      blood by increasing the amount of urine produced. Hence the blood glucose levels are
      significantly decreased and the efficacy of EGT001442 can be established by assessing the
      three months average blood glucose levels (HbA1c). Due to the increased urinary output, the
      effect of EGT001442 on blood pressure levels are also assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Hemoglobin A1c levels at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from basline in HbA1c levels in placebo and treatment group at end of 24 weeks treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic and diastolic blood pressure at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from basline in systolic and diastolic blood pressure in placebo and treatment group at 24 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight at 24 weeks treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes from baseline in body weight in placebo and treatment group at 24 weeks treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hemoglobin A1c level over 96 weeks time</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in HbA1c level over 96 weeks time in plaebo and treatment group. The treatment group received 24 weeks treatment with EGT0001442.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events during 96 weeks time</measure>
    <time_frame>96 weeks</time_frame>
    <description>Number of participants with adverse events in placebo and treatment group during 96 weeks time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>EGT0001442</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>EGT0001442 20 mg capsule, daily, 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGT0001442</intervention_name>
    <arm_group_label>EGT0001442</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥18 years old

          -  Diagnosed with type 2 diabetes

          -  Body mass index (BMI) ≤ 45 kg/m2

          -  HbA1c between 7 and 10% (inclusive) at screening

          -  FPG &lt;250 mg/dL at screening for subjects not treated with oral anti-diabetic therapies
             or FPG &lt;240 mg/dL at screening for subjects treated with anti-diabetic therapies

          -  Diabetes currently treated with diet and exercise only or diet and exercise along with
             one approved oral anti-diabetic agent

          -  If taking anti-diabetic medication, dose and regimen must be stable for past 3 months

          -  If taking anti-hypertensive medication, dose and regimen must be stable for past 3
             months

          -  If taking lipid modifying therapy, dose and regimen must be stable for past 3 months

          -  Blood glucose &lt;250 mg/dL based on finger stick blood glucose for all subjects at
             randomization

        Exclusion Criteria:

          -  Hemoglobinopathy that affects HbA1c measurement

          -  Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor
             based therapy)

          -  Genitourinary tract infection within 6 weeks of screening

          -  Greater than 2 episodes of genitourinary tract infection in the past year

          -  History of kidney stones, bladder malfunction or other significant risk factor for
             urinary tract infections

          -  eGFR, as calculated by the modification of diet in renal disease study equation
             (MDRD), &lt; 50 mL/min/1.73 m2

          -  Abnormal tests of liver function ALT, AST or bilirubin ≥ 3x ULN

          -  Diagnosis of retinopathy or significant nephropathy (eGFR &lt; 50 mL/min/1.73 m2

          -  Uncontrolled hypertension (systolic blood pressure &gt;160 or diastolic blood pressure
             &gt;95)

          -  Not willing to use effective birth control, if female with child-bearing potential

          -  Life expectancy &lt; 2 years

          -  New York Heart Association (NYHA) Class 4 heart failure

          -  Sera positive of HCV, HIV, or positive on drug screen

          -  Currently participating in another interventional trial

          -  Previous treatment with EGT0001442 or EGT0001474

          -  Not able to comply with the study scheduled visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason W Freeman, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 7</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8</name>
      <address>
        <city>Munroe Falls</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 7</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011 Jan;34 Suppl 1:S11-61. doi: 10.2337/dc11-S011.</citation>
    <PMID>21193625</PMID>
  </reference>
  <reference>
    <citation>Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):31-8. Review.</citation>
    <PMID>15624123</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612. Epub 2010 Jun 21.</citation>
    <PMID>20566676</PMID>
  </reference>
  <reference>
    <citation>Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008 Jun;57(6):1723-9. doi: 10.2337/db07-1472. Epub 2008 Mar 20.</citation>
    <PMID>18356408</PMID>
  </reference>
  <reference>
    <citation>Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009 May;85(5):520-6. doi: 10.1038/clpt.2008.251. Epub 2009 Jan 7.</citation>
    <PMID>19129748</PMID>
  </reference>
  <reference>
    <citation>Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 May;85(5):513-9. doi: 10.1038/clpt.2008.250. Epub 2009 Jan 7. Erratum in: Clin Pharmacol Ther. 2009 May;85(5):558.</citation>
    <PMID>19129749</PMID>
  </reference>
  <reference>
    <citation>Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Review.</citation>
    <PMID>20205482</PMID>
  </reference>
  <reference>
    <citation>Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003 Nov;14(11):2873-82.</citation>
    <PMID>14569097</PMID>
  </reference>
  <reference>
    <citation>Sicree, R., Shaw, J., and Zimmet, P. (2010). The Global Burden - Diabetes and Impaired Glucose Tolerance (Baker IDI Heart and Diabetes Institute).</citation>
  </reference>
  <reference>
    <citation>van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet. 2002 Dec;111(6):544-7. Epub 2002 Sep 27.</citation>
    <PMID>12436245</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <disposition_first_submitted>July 23, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 29, 2014</disposition_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

